IE
XFOR icon

Israel Englander’s X4 Pharmaceuticals XFOR Stock Holding History

Israel Englander’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,210,514
Closed -$5M – 6470
2026
Q1 		$5M Buy
1,210,514
+1,154,536
+2,062% +$4.32M ﹤0.01% 2948
2025
Q4 		$224K Sell
55,978
-8,817
-14% -$32K ﹤0.01% 5419
2025
Q3 		$222K Sell
64,795
-13,266
-17% -$34.2K ﹤0.01% 5496
2025
Q2 		$148K Buy
78,061
+69,436
+805% +$284K ﹤0.01% 5447
2025
Q1 		$61.2K Hold
8,625
– – ﹤0.01% 5510
2024
Q4 		$190K Sell
8,625
-3,482
-29% -$55.5K ﹤0.01% 5325
2024
Q3 		$243K Buy
12,107
+660
+6% +$13.8K ﹤0.01% 5324
2024
Q2 		$199K Buy
11,447
+2,822
+33% +$92.3K ﹤0.01% 5142
2024
Q1 		$360K Sell
8,625
-46,852
-84% -$1.3M ﹤0.01% 5025
2023
Q4 		$1.4M Sell
55,477
-65,055
-54% -$1.58M ﹤0.01% 3895
2023
Q3 		$3.94M Sell
120,532
-61,188
-34% -$2.67M ﹤0.01% 2929
2023
Q2 		$10.6M Buy
181,720
+145,713
+405% +$7.49M 0.01% 1971
2023
Q1 		$940K Sell
36,007
-2,441
-6% -$71.6K ﹤0.01% 4149
2022
Q4 		$1.15M Buy
38,448
+34,683
+921% +$1.64M ﹤0.01% 4032
2022
Q3 		$193K Buy
3,765
+1,175
+45% +$40.6K ﹤0.01% 5678
2022
Q2 		$75K Sell
2,590
-10,875
-81% -$414K ﹤0.01% 6039
2022
Q1 		$707K Buy
13,465
+6,716
+100% +$385K ﹤0.01% 4852
2021
Q4 		$464K Sell
6,749
-2,163
-24% -$274K ﹤0.01% 5121
2021
Q3 		$1.41M Sell
8,912
-3,955
-31% -$651K ﹤0.01% 4301
2021
Q2 		$2.51M Buy
+12,867
New +$3.24M ﹤0.01% 3673
2020
Q2 		– Sell
-552
Closed -$165K – 4657
2020
Q1 		$165K Sell
552
-1,659
-75% -$471K ﹤0.01% 3447
2019
Q4 		$710K Sell
2,211
-4,077
-65% -$1.46M ﹤0.01% 3170
2019
Q3 		$2.4M Buy
6,288
+1,233
+24% +$488K ﹤0.01% 2336
2019
Q2 		$2.27M Buy
+5,055
New +$2.57M ﹤0.01% 2325
2018
Q1 		– Sell
-130
Closed -$299K – 4141
2017
Q4 		$299K Buy
+130
New +$329K ﹤0.01% 3351

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Israel Englander's XFOR Position: Q2 2026 in Review

Israel Englander sold out of X4 Pharmaceuticals (XFOR) in Q2 2026, closing a stake of 1,210,514 shares — an estimated $5M sold.

Israel Englander first reported a position in XFOR in Q4 2017 and held it in 25 quarters. The position peaked at $10.6M in Q2 2023. 88 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Israel Englander reported no remaining X4 Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 1,210,514 X4 Pharmaceuticals shares in Q2 2026, an estimated $5M.
  • Israel Englander first reported a position in X4 Pharmaceuticals in Q4 2017 and held it in 25 quarters.
  • Israel Englander's X4 Pharmaceuticals position peaked at $10.6M in Q2 2023.
  • 88 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.